GLP-1 & compounded medication availability in Nevada (2026)

Nevada’s pharmacy regulators have gone further than most: in June 2025 they told every compounding licensee in writing to stop producing copies of the two GLP-1 injectables now that the federal shortages are over. What remains is the narrow, patient-specific path the federal framework itself preserves, and this page states that plainly rather than talking around it. All ten lines below, then the notice itself, cited.

Restrictive state

Availability facts last reviewed: November 16, 2026

What ships to Nevada: all ten lines

Availability of all ten OrderlyMeds product lines in Nevada, with typical delivery times and notes
Product lineAvailable in Nevada?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Patient-specific prescriptions only. Nevada’s June 2025 notice is cited below. Read it first.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same caveat as the GLP-1 row; the notice names both medications.
NAD+ Yes 8–10 business days Dispensed from licensed partner pharmacies.
Sermorelin Yes 8–10 business days Unaffected by the GLP-1 notice; standard ordering flow.
Glutathione No N/A Not in the current OrderlyMeds catalog.
BPC-157 Yes 8–10 business days Compounded injectable; a different question from the GLP-1 notice. Federal record below.
TB-500 Yes 8–10 business days Compounded injectable; its federal section is below.
KPV No N/A Not carried in any state; the formulary is injectable-form only.
Epitalon Yes 8–10 business days Compounded injectable; federal facts below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record below stands on its own.

The “Yes” rows above come with the regulator section below attached, on this page more than most. Nevada facts were last reviewed on November 16, 2026.

Research peptides in Nevada: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Nevada’s June 2025 notice concerns the two GLP-1 injectables; it does not name these five lines. Four of them ship to Nevada: BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables on patient-specific prescriptions. KPV is not carried anywhere. Each section below states that line’s own federal record, identical on every state page, because those facts do not move at a state border.

BPC-157 in Nevada

BPC-157 ships to Nevada as a compounded injectable on a patient-specific prescription, which is a separate question from the GLP-1 notice covered in the regulator section. The federal facts below still apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Nevada

Nevada orders are filled as compounded injectables under patient-specific prescriptions; the federal record is below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Nevada

KPV is not carried, in Nevada or any state. The injectable-only formulary is the reason.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Nevada

In the Nevada offering as a compounded injectable; its federal position below is unchanged by the state’s GLP-1 notice.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Nevada

Ships to Nevada as a compounded injectable, patient-specific prescription required. Read its own federal record below, because it is not the other four’s.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Nevada’s pharmacy regulators say, and why to read it before ordering a GLP-1

Nevada’s position is the most explicit of any state on this page so far, and it deserves to be read directly rather than summarized away. Four cited positions below, starting with the June 2025 notice itself.

On June 2, 2025, the Nevada State Board of Pharmacy notified all licensees and registrants that, with FDA’s declaratory orders resolving the tirzepatide and semaglutide shortages, 503A and 503B pharmacies must cease compounding, distributing, and dispensing compounded tirzepatide and semaglutide injection products, and directed compounding pharmacies to FDA’s January 2018 guidance on essential copies of commercially available drugs to evaluate the remaining exceptions. Source: Nevada State Board of Pharmacy — June 2, 2025 notice (PDF).

The same notice reminds 503A pharmacies that they are not permitted to sell compounded medications to practitioners, points licensees to NAC 639.757 and associated compounding regulations as amended effective November 15, 2024, and states that continued compounding of the named products may draw a citation or administrative fine under NRS 639.2895. Source: Nevada State Board of Pharmacy — June 2, 2025 notice (PDF).

A pharmacy located outside Nevada must be licensed by the Nevada State Board of Pharmacy before dispensing to Nevada patients; NRS 639.233 — among the provisions the June 2025 notice cites — governs that licensure. Source: Nevada State Board of Pharmacy.

Nevada recognizes a provider-patient relationship established and maintained through telehealth where clinically appropriate, including a bona fide relationship where the patient received an examination within the six months preceding the prescription, in person or through telehealth. Source: CCHP Policy Finder — Nevada.

What we do with that: OrderlyMeds dispenses compounded GLP-1s to Nevada only under patient-specific prescriptions documenting an individual clinical need, which is the narrow space the federal essential-copies framework itself preserves and the framework Nevada’s notice points pharmacies to. We have flagged this page’s GLP-1 rows for our compliance reviewer precisely because Nevada has put its position in writing. If the state’s stance moves, this page moves with the data feed behind it, in either direction.

Nevada availability FAQs

Is compounded semaglutide available in Nevada?

Yes, narrowly: only as a patient-specific prescription documenting an individual clinical need, the space the federal essential-copies framework preserves. Nevada's June 2025 notice, cited above, is why that caveat leads this answer.

What did Nevada's June 2025 notice do?

It told 503A and 503B pharmacies to stop compounding, distributing, and dispensing compounded tirzepatide and semaglutide injection products after the federal shortages ended, pointing to FDA's essential-copies guidance for the remaining exceptions. The primary document is linked above.

Can I get BPC-157 or other research peptides shipped to Nevada?

Four of the five ship to Nevada as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not. The June 2025 notice concerns the two GLP-1 injectables; each peptide section above states its own federal record.

How long does delivery to Nevada take?

8–10 business days from signup, per our published window.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone